Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) pipeline Target constitutes close to 8 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes. The latest report Insulin Like Growth Factor II - Pipeline Review, H1 2019, outlays comprehensive information on the Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.